ACK2-dependent mechanism for activation of the JAK-STAT signaling pathway

Blood

Volumn 118, Issue 1, 2011, Pages 156-166

  Zheng, Ying ^a   Qin, Hongwei ^a   Frank, Stuart J ^a,b   Deng, Luqin ^b   Litchfield, David W ^c   Tefferi, Ayalew ^d   Pardanani, Animesh ^d   Lin, Fang Tsyr ^a   Li, Jingzhi ^a   Sha, Bingdong ^a   Benveniste, Etty N ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c WESTERN UNIVERSITY   (Canada)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE II; CYTOKINE; JANUS KINASE 1; JANUS KINASE 2; PHENYLALANINE; SUPPRESSOR OF CYTOKINE SIGNALING 3; VALINE; GLYCOGEN PHOSPHORYLASE; JAK1 PROTEIN, HUMAN; JAK1 PROTEIN, MOUSE; JAK2 PROTEIN, HUMAN; JAK2 PROTEIN, MOUSE; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; CELL LINE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; ANIMAL; APOPTOSIS; BLOOD DISEASE; CELL SURVIVAL; CYTOLOGY; DRUG ANTAGONISM; FIBROBLAST; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CASEIN KINASE II; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL SURVIVAL; FIBROBLASTS; HEMATOLOGIC NEOPLASMS; HUMANS; JANUS KINASE 1; JANUS KINASE 2; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MICE; PHOSPHORYLASE A; POLYCYTHEMIA VERA; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 79960119979     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-266320     Document Type: Article

References (48)

1. Chen S-H, Benveniste EN. Oncostatin M: a pleiotropic cytokine in the central nervous system. Cytokine Growth Factor Rev. 2004;15(5):379-391. (Pubitemid 39144383)
2. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol. 2003;3(11):900-911. (Pubitemid 37411719)
3. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93(3):385-395. (Pubitemid 28232083)
4. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood. 2008;112(6):2190-2198.
5. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397. (Pubitemid 40544655)
6. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790. (Pubitemid 40570926)
7. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148. (Pubitemid 40663494)
8. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061. (Pubitemid 40386783)
9. Xing S, Wanting TH, Zhao W, et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood. 2008;111(10):5109-5117.
10. Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108(5):1652-1660. (Pubitemid 44316134)
11. Bumm TG, Elsea C, Corbin AS, et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res. 2006;66(23):11156- 11165. (Pubitemid 46009942)
12. Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7(9):673-683. (Pubitemid 47327415)
13. Vilk G, Weber JE, Turowec JP, et al. Protein kinase CK2 catalyzes tyrosine phosphorylation in mammalian cells. Cell Signal. 2008;20(11):1942-1951.
14. Litchfield DW. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J. 2003;369(pt 1):1-15. (Pubitemid 36174119)
15. Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2? Faseb J. 2003;17(3):349-368.
16. Lou DY, Dominguez I, Toselli P, Landesman-Bollag E, O'Brien C, Seldin DC. The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development. Mol Cell Biol. 2008;28(1):131-139.
17. Buchou T, Vernet M, Blond O, et al. Disruption of the regulatory β subunit of protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic lethality. Mol Cell Biol. 2003;23(3):908-915. (Pubitemid 36133509)
18. Piazza FA, Ruzzene M, Gurrieri C, et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood. 2006;108(5):1698-1707. (Pubitemid 44316140)
19. Kim JS, Eom JI, Cheong JW, et al. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res. 2007;13(3):1019-1028.
20. Duncan JS, Litchfield DW. Too much of a good thing: The role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta. 2008;1784(1):33-47.
21. Channavajhala P, Seldin DC. Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene. 2002;21(34):5280-5288. (Pubitemid 34948139)
22. Landesman-Bollag E, Channavajhala PL, Cardiff RD, Seldin DC. p53 deficiency and misexpression of protein kinase CK2α collaborate in the development of thymic lymphomas in mice. Oncogene. 1998;16(23):2965-2974. (Pubitemid 28297717)
23. Chen S-H, Gillespie GY, Benveniste EN. Divergent effects of Oncostatin M on astroglioma cells: Influence on cell proliferation, invasion and expression of matrix metalloproteinases. Glia. 2006;53(2):191-200.
24. Loesch K, Deng L, Cowan JW, et al. Janus kinase 2 influences growth hormone receptor metalloproteolysis. Endocrinology. 2006;147(6):2839-2849. (Pubitemid 43764620)
25. Deng L, He K, Wang X, et al. Determinants of growth hormone receptor down-regulation. Mol Endocrinol. 2007;21(7):1537-1551. (Pubitemid 47001080)
26. Dong Y, Tang L, Letterio JJ, Benveniste EN. The Smad3 protein is involved in TGF-beta inhibition of class II transactivator and class II MHC expression. J Immunol. 2001;167(1):311-319. (Pubitemid 32567794)
27. Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia. 2009;23(8):1441-1445.
28. Duncan JS, Gyenis L, Lenehan J, et al. An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets. Mol Cell Proteomics. 2008;7(6):1077-1088. (Pubitemid 351943955)
29. Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol. 2000;20(10):3387-3395. (Pubitemid 30243884)
30. Qin H, Wilson C, Roberts K, Baker B, Zhao X, Benveniste E. IL-10 inhibits lipopolysaccharide-induced cd40 gene expression through induction of suppressor of cytokine signaling-3. J Immunol. 2006;177(11):7761-7771. (Pubitemid 44846292)
31. Choi YH, Bernardi R, Pandolfi PP, Benveniste EN. The promyelocytic leukemia protein functions as a negative regulator of IFN-gamma signaling. Proc Natl Acad Sci U S A. 2006;103(49):18715-18720. (Pubitemid 44913476)
32. Scaglioni PP, Yung TM, Cai LF, et al. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell. 2006;126(2):269-283. (Pubitemid 44092959)
33. Seldin DC, Landesman-Bollag E, Farago M, Currier N, Lou D, Dominguez I. CK2 as a positive regulator of Wnt signalling and tumourigenesis. Mol Cell Biochem. 2005;274(1-2):63-67. (Pubitemid 41001501)
34. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 1998;93(3):397-409. (Pubitemid 28232084)
35. Gyenis L, Litchfield DW. The emerging CK2 interactome: insights into the regulation and functions of CK2. Mol Cell Biochem. 2008;316(1-2):5-14.
36. Robertson SA, Koleva RI, Argetsinger LS, et al. Regulation of Jak2 function by phosphorylation of Tyr317 and Tyr637 during cytokine signaling. Mol Cell Biol. 2009;29(12):3367-3378.
37. Stehmeier P, Muller S. Phospho-regulated SUMO interaction modules connect the SUMO system to CK2 signaling. Mol Cell. 2009;33(3):400-409.
38. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798-809.
39. Hedvat M, Huszar D, Herrmann A, et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009;16(6):487-497.
40. Ahmad KA, Wang G, Slaton J, Unger G, Ahmed K. Targeting CK2 for cancer therapy. Anticancer Drugs. 2005;16(10):1037-1043. (Pubitemid 41565768)
41. Ruzzene M, Penzo D, Pinna LA. Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cellspecific protein 1 (HS1) in Jurkat cells. Biochem J. 2002;364(pt 1):41-47.
42. Pagano MA, Poletto G, Di Maira G, et al. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem. 2007;8(1):129-139. (Pubitemid 46121580)
43. Pagano MA, Meggio F, Ruzzene M, Andrzejewska M, Kazimierczuk Z, Pinna LA. 2-Dimethylamino-4,5,6,7-tetrabromo-1Hbenzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochem Biophys Res Commun. 2004;321(4):1040-1044.
44. Slaton JW, Unger GM, Sloper DT, Davis AT, Ahmed K. Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Mol Cancer Res. 2004;2(12):712-721.
45. Wang Y, Fiskus W, Chong DG, et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood. 2009;114(24):5024-5033.
46. Mishra S, Reichert A, Cunnick J, et al. Protein kinase CKIIalpha interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells. Oncogene. 2003;22(51):8255-8262. (Pubitemid 37485518)
47. Mishra S, Pertz V, Zhang B, et al. Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2. Leukemia. 2007;21(1):178-180. (Pubitemid 44921853)
48. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia. 2008;22(1):23-30.